相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer
I. A. McNeish et al.
ANNALS OF ONCOLOGY (2014)
New Chemical Scaffolds for Human African Trypanosomiasis Lead Discovery from a Screen of Tyrosine Kinase Inhibitor Drugs
Ranjan Behera et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Cancer Statistics, 2014
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904
Robert L. Coleman et al.
EUROPEAN JOURNAL OF CANCER (2014)
SGO guidance document for clinical trial designs in ovarian cancer: A changing paradigm
Thomas J. Herzog et al.
GYNECOLOGIC ONCOLOGY (2014)
Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper
Thomas J. Herzog et al.
GYNECOLOGIC ONCOLOGY (2014)
A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer
Eric L. Eisenhauer et al.
GYNECOLOGIC ONCOLOGY (2014)
A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube
Thomas J. Herzog et al.
GYNECOLOGIC ONCOLOGY (2014)
Bevacizumab in Treatment of High-Risk Ovarian Cancer-A Cost-Effectiveness Analysis
John K. Chan et al.
ONCOLOGIST (2014)
Cost Effectiveness of Alternative Strategies for Incorporating Bevacizumab Into the Primary Treatment of Ovarian Cancer
Jason C. Barnett et al.
CANCER (2013)
Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer
Andrea R. Hagemann et al.
GYNECOLOGIC ONCOLOGY (2013)
Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer
Israel Zighelboim et al.
GYNECOLOGIC ONCOLOGY (2013)
A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy
Robert M. Wenham et al.
GYNECOLOGIC ONCOLOGY (2013)
Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma
Todd D. Tillmanns et al.
GYNECOLOGIC ONCOLOGY (2013)
A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma
Thomas J. Herzog et al.
GYNECOLOGIC ONCOLOGY (2013)
Weekly Administration of Bevacizumab, Gemcitabine, and Oxaliplatin in Patients With Recurrent and Refractory Ovarian Cancer A Preliminary Result of 19 Cases
Yuji Ikeda et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2013)
Should Bevacizumab Be Continued After Progression on Bevacizumab in Recurrent Ovarian Cancer?
Floor J. Backes et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2013)
Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial
Noriyuki Katsumata et al.
LANCET ONCOLOGY (2013)
Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer
C. F. Verschraegen et al.
ANNALS OF ONCOLOGY (2012)
Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I/II trial of the AGO study group
A. du Bois et al.
BRITISH JOURNAL OF CANCER (2012)
A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer
Marcela G. del Carmen et al.
GYNECOLOGIC ONCOLOGY (2012)
Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer
Ursula A. Matulonis et al.
GYNECOLOGIC ONCOLOGY (2012)
Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer
Beth Y. Karlan et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Treatment Patterns and Clinical Outcomes in Patients With Metastatic Colorectal Cancer Initially Treated with FOLFOX-Bevacizumab or FOLFIRI-Bevacizumab: Results From ARIES, a Bevacizumab Observational Cohort Study
Johanna C. Bendell et al.
ONCOLOGIST (2012)
A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study
J. J. Biagi et al.
ANNALS OF ONCOLOGY (2011)
Combined Weekly Topotecan and Biweekly Bevacizumab in Women With Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer Results of a Phase 2 Study
Kathryn F. McGonigle et al.
CANCER (2011)
Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer
David M. O'Malley et al.
GYNECOLOGIC ONCOLOGY (2011)
Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers
Kazuya Kudoh et al.
GYNECOLOGIC ONCOLOGY (2011)
Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group
R. Ramasubbaiah et al.
GYNECOLOGIC ONCOLOGY (2011)
Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial
Daniela Matei et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase II Study of Intraperitoneal Paclitaxel Plus Cisplatin and Intravenous Paclitaxel Plus Bevacizumab As Adjuvant Treatment of Optimal Stage II/III Epithelial Ovarian Cancer
Jason A. Konner et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
At What Cost Does a Potential Survival Advantage of Bevacizumab Make Sense for the Primary Treatment of Ovarian Cancer? A Cost-Effectiveness Analysis
David E. Cohn et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies
A. du Bois et al.
ANNALS OF ONCOLOGY (2010)
Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity
J-M Lee et al.
BRITISH JOURNAL OF CANCER (2010)
Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer
Martin Poelcher et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Overexpression of Tumor Vascular Endothelial Growth Factor A May Portend an Increased Likelihood of Progression in a Phase II Trial of Bevacizumab and Erlotinib in Resistant Ovarian Cancer
Setsuko K. Chambers et al.
CLINICAL CANCER RESEARCH (2010)
Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2
Christina M. Annunziata et al.
CLINICAL CANCER RESEARCH (2010)
AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia
Nuria Barbarroja et al.
EXPERIMENTAL HEMATOLOGY (2010)
The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab
M. P. Smerdel et al.
GYNECOLOGIC ONCOLOGY (2010)
A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
Michael Friedlander et al.
GYNECOLOGIC ONCOLOGY (2010)
Effect of AEE788 and/or Celecoxib on colon cancer cell morphology using advanced microscopic techniques
P. Venkatesan et al.
MICRON (2010)
Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer
J. D. Hurt et al.
GYNECOLOGIC ONCOLOGY (2009)
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
J. Randolph Hecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis - A hoosier oncology group trial
Daniela Matei et al.
CANCER (2008)
Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer
Debra L. Richardson et al.
GYNECOLOGIC ONCOLOGY (2008)
Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study
Russell J. Schilder et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and princess Margaret hospital phase II consortia
Agustin A. Garcia et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Preclinical studies on the influence of the tyrosine kinase inhibitor AEE788 on malignant properties of renal cell carcinoma cells
S. A. Wedel et al.
UROLOGE (2008)
Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer
Justin C. Chura et al.
GYNECOLOGIC ONCOLOGY (2007)
Hypoxia modulation and radiosensitization by the novel dual EGFR and VEGFR inhibitor AEE788 in spontaneous and related allograft tumor models
Christoph Oehler-Jaenne et al.
MOLECULAR CANCER THERAPEUTICS (2007)
A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer - A phase II clinical study with proteomic profiling
Edwin M. Posadas et al.
CANCER (2007)
Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma
Chunhua Lu et al.
CLINICAL CANCER RESEARCH (2007)
Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211)
D. S. Alberts et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2007)
Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: Mutational and functional analysis
Constantine S. Mitsiades et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer
John V. Heymach et al.
CLINICAL CANCER RESEARCH (2006)
Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers
RL Coleman et al.
GYNECOLOGIC ONCOLOGY (2006)
Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice
S Yazici et al.
PROSTATE (2005)
Targeting multiple signal transduction pathways in lung cancer
Alex A. Adjei
CLINICAL LUNG CANCER (2005)
Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation
MN Younes et al.
CANCER RESEARCH (2005)
Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2
J Oliner et al.
CANCER CELL (2004)
Cost-utility of initial medical management for Crohn's disease perianal fistulae
KO Arseneau et al.
GASTROENTEROLOGY (2001)
分享论文
